Morphosys rises on long-term data from lymphoma drug study

Morphosys AG

29/09/2022 10:26

** Shares in Morphosys  MORG.DE  rise 2.8% after the German
biotech group presented long-term data from lymphoma drug L-MIND
study suggesting durable response to treatment with Monjuvi
 urn:newsml:reuters.com:*:nFWN30Z15K
    ** The Munich-based firm says that it observed a complete
response in 23 of 27 patients, including four who were
refractory to their primary therapy in study
    ** "MOR shares gained 2.5% in extended US trading with very
low volume" a local trader says
    ** Morphosys shares also rose 19.9% on Wednesday as its peer
Roche  ROG.S  on positive read-across from rival Alzheimer's
drug study  urn:newsml:reuters.com:*:nL8N30Z1A1
    ** The stock is among the best performers on Germany's
small-cap index  .SDAXI 
    ($1 = 1.0358 euros)
 (Reporting by Ozan Ergenay)
 ((ozan.ergenay@thomsonreuters.com))